Back to Newsroom

International Stem Cell Corporation Publishes Results of Safety Studies Conducted in Support of the First Human Pluripotent Stem Cell Based Therapy for Parkinson’s Disease

CARLSBAD, Calif., Oct. 05, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that it has published the results of its preclinical safety studies. The data from a series ofin vitro and in vivo preclinical studies show that the company’s proprietary ISC-hpNSC® readily expandable neural stem cells are devoid of undifferentiated pluripotent stem cells and are safe for transplantation. The full manuscript titled, “Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson’s Disease,” was published in the September 30 issue of Scientific Reports, a multidisciplinary journal from the publishers of Nature.

Click here to read the full release